Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Imatinib can act as an Allosteric Activator of Abl Kinase

Journal of Molecular Biology(2021)10.1016/j.jmb.2021.167349Source: DataRank Database

Imatinib can act as an Allosteric Activator of Abl Kinase is a research paper published in Journal of Molecular Biology (2021). On theSindex it has a DataRank of 0. It has been cited 24 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access24 citations

Download PDF

Cite:

Linked data & code

gen pdb

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (12 grants)Impact (FWCI 1.84)OA: greenTopics (57)IDs (PubMed, PMC, OpenAlex)Annotations (2)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (5)

Tamjeed Saleh ORCID,P. Rossi ORCID,Darcie J. Miller,Charalampos G. Kalodimos ORCID,Tao Xie ORCID

Live enrichment

PubMed:34774565 PMC:PMC8752476 OpenAlex:https://openalex.org/W3213203600

National Institutes of Health

Grant: R35 GM122462

Basic Energy Sciences

Grant: S10_RR028976

Basic Energy Sciences

Grant: S10_RR25528

Basic Energy Sciences

Grant: W-31-109-Eng-38

NCRR NIH HHS

Grant: S10 RR025528

NIAID NIH HHS

Grant: R01 AI121858

NCRR NIH HHS

Grant: S10 RR028976

National Institutes of Health

Grant: 5R35GM122462-08

Structure and functional mechanisms of molecular chaperones and protein kinases

Argonne National Laboratory

U.S. Department of Energy

Office of Science

American Lebanese Syrian Associated Charities

FWCI

1.84

Citation Percentile

0.9%

Citation Trend

2022

2023

2024

2025

2026

greenLicense: Elsevier TDM

repositoryhttps://www.ncbi.nlm.nih.gov/pmc/articles/8752476

publisherhttps://api.elsevier.com/content/article/PII:S0022283621005866?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S0022283621005866?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.jmb.2021.167349

Fields of Study

Chronic Myeloid Leukemia TreatmentsEosinophilic Disorders and SyndromesQuinazolinone synthesis and applications0301 basic medicine0303 health sciences03 medical and health sciencesAllosteric RegulationAllosteric SiteAntineoplastic AgentsCatalytic DomainDrug Resistance, NeoplasmHumansImatinib MesylateLeukemia, Myelogenous, Chronic, BCR-ABL PositiveModels, MolecularMutationProtein Kinase Inhibitors

MeSH Terms

Imatinib MesylateAllosteric RegulationAllosteric SiteAntineoplastic AgentsHumansModels, MolecularMutationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveDrug Resistance, NeoplasmCatalytic DomainProtein Kinase Inhibitors

Keywords

Allosteric regulationImatinibABLChemistryImatinib mesylateActivator (genetics)Chronic myelogenous leukemiaBiologyBiochemistryCancer researchLeukemiaTyrosine kinaseEnzymeReceptorGeneticsMyeloid leukemiaDrug resistanceNMRBcr-ablAllosteric ActivatorModels, MolecularAntineoplastic AgentsDrug Resistance, NeoplasmCatalytic DomainLeukemia, Myelogenous, Chronic, BCR-ABL PositiveMutationHumansProtein Kinase InhibitorsAllosteric Site

Sustainable Development Goals

SDG 3: 3. Good healthSDG 0: Good health and well-being

Imatinib can act as an Allosteric Activator of Abl Kinase

FAIR Checklist

Authors (5)

Funding (12 grants)

Impact

Open Access

Topics

Annotations (Europe PMC)